Prophylactic probiotics for cancer therapy-induced diarrhoea: A meta-analysis

Simple item page
dc.contributor.authorWardill, H.R.
dc.contributor.authorVan Sebille, Y.Z.A.
dc.contributor.authorCiorba, M.A.
dc.contributor.authorBowen, J.M.
dc.date.issued2018
dc.description.abstractPURPOSE OF REVIEW: Strong preclinical data support prophylactic probiotics as an effective preventive strategy for diarrhoea secondary to anticancer therapies. To determine the composite evidence that this approach translates to the clinic, we performed a meta-analysis of randomized controlled trials (RCTs) of prophylactic probiotics for the prevention of cancer therapy-induced diarrhoea. RECENT FINDINGS: A three-step search strategy was used to identify relevant studies (1 June 2000-1 June 2017) investigating probiotic intervention for diarrhoea secondary to any cancer therapy (cytotoxic, targeted and immunotherapies). RCTs across PubMed, Embase, CINAHL and CENTRAL were assessed for eligibility and assessed using RevMan 5.3 (The Cochrane Collaboration). Seven trials with a total of 1091 patients were included in this meta-analysis. Compared with placebo, prophylactic probiotics did not prevent or reduce the overall incidence of diarrhoea or severe CTCAE Grade at least 3 diarrhoea [relative risk (RR) = 0.81, 95% confidence interval (95% CI) = 0.60-1.09, Z = 1.41, P = 0.16; RR = 0.54, 95% CI = 0.25-1.16, Z = 1.58, P = 0.11], nor did it influence the use of rescue medication (RR = 0.93, 95% CI = 0.53-1.65, Z = 0.24, P = 0.81). SUMMARY: Current evidence does not support widespread implementation of probiotics for diarrhoea secondary to cytotoxic therapy and the tyrosine kinase inhibitor, dacomitinib. Research efforts should be diverted to pair specific forms of gastrointestinal toxicity and their unique microbial phenotype to develop the ideal microbial protectant.
dc.description.statementofresponsibilityHannah R. Wardill, Ysabella Z.A. Van Sebille, Matthew A. Ciorba, and Joanne M. Bowen
dc.identifier.citationCurrent Opinion in Supportive and Palliative Care, 2018; 12(2):187-197
dc.identifier.doi10.1097/SPC.0000000000000338
dc.identifier.issn1751-4258
dc.identifier.issn1751-4266
dc.identifier.orcidWardill, H.R. [0000-0002-6613-3661]
dc.identifier.orcidBowen, J.M. [0000-0003-0876-0031]
dc.identifier.urihttps://hdl.handle.net/2440/139018
dc.language.isoen
dc.publisherLippincott, Williams & Wilkins
dc.relation.granthttp://purl.org/au-research/grants/nhmrc/1140992
dc.rights© 2018 Wolters Kluwer Health, Inc. All rights reserved.
dc.source.urihttps://doi.org/10.1097/spc.0000000000000338
dc.subjectcancer therapy; chemo/radiotherapy; diarrhoea; meta-analysis; probiotics
dc.subject.meshHumans
dc.subject.meshNeoplasms
dc.subject.meshDiarrhea
dc.subject.meshAntineoplastic Agents
dc.subject.meshProbiotics
dc.subject.meshRandomized Controlled Trials as Topic
dc.titleProphylactic probiotics for cancer therapy-induced diarrhoea: A meta-analysis
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Physiology publications